Altimmune (ALT) Projected to Release Earnings on Thursday

Altimmune (NASDAQ:ALT) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $0.00 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. On average, analysts expect Altimmune to post ($0.58) EPS for the current fiscal year and ($0.54) EPS for the next fiscal year.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $2.04 on Wednesday. The company has a current ratio of 26.78, a quick ratio of 26.78 and a debt-to-equity ratio of 0.07. The stock has a 50 day simple moving average of $2.78 and a 200-day simple moving average of $3.27. The company has a market cap of $396.82 million, a PE ratio of -2.62 and a beta of 0.16. Altimmune has a 12-month low of $1.99 and a 12-month high of $6.44.

Wall Street Analyst Weigh In

ALT has been the topic of several analyst reports. Evercore restated an “outperform” rating on shares of Altimmune in a research report on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, September 21st. Finally, HC Wainwright reissued a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.33.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for obesity and liver diseases. The company’s research programs are designed to address metabolic and inflammatory conditions with significant unmet medical needs.

Altimmune’s lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being evaluated for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease.